Defence Therapeutics (XCNQ:DTC) Interest Expense : C$-0.26 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Defence Therapeutics's interest expense for the three months ended in Dec. 2023 was C$ -0.06 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.26 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Defence Therapeutics's Operating Income for the three months ended in Dec. 2023 was C$ -8.31 Mil. Defence Therapeutics's Interest Expense for the three months ended in Dec. 2023 was C$ -0.06 Mil. Defence Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Defence Therapeutics Interest Expense Historical Data

The historical data trend for Defence Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Interest Expense Chart

Defence Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Interest Expense

Defence Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial										-	-0.05	-0.11	-0.10	-0.06

Defence Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.26 Mil.

Defence Therapeutics (XCNQ:DTC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Defence Therapeutics's Interest Expense for the three months ended in Dec. 2023 was C$-0.06 Mil. Its Operating Income for the three months ended in Dec. 2023 was C$-8.31 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was C$0.02 Mil.

Defence Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Defence Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Defence Therapeutics (XCNQ:DTC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

DTCFF:USA DTC:Germany

Address

200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6

Website

https://www.defencetherapeutics.com

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.

Executives

Sarkis Meterissian

Director